Export 2 results:
Author Title Type [ Year(Desc)]
Filters: Author is Paris, Robert M  [Clear All Filters]
2012
M. L. Robb, Rerks-Ngarm, S., Nitayaphan, S., Pitisuttithum, P., Kaewkungwal, J., Kunasol, P., Khamboonruang, C., Thongcharoen, P., Morgan, P., Benenson, M., Paris, R. M., Chiu, J., Adams, E., Francis, D., Gurunathan, S., Tartaglia, J., Gilbert, P., Stablein, D., Michael, N. L., and Kim, J. H., “Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.”, Lancet Infect Dis, vol. 12, no. 7, pp. 531-7, 2012.
M. S. de Souza, Ratto-Kim, S., Chuenarom, W., Schuetz, A., Chantakulkij, S., Nuntapinit, B., Valencia-Micolta, A., Thelian, D., Nitayaphan, S., Pitisuttithum, P., Paris, R. M., Kaewkungwal, J., Michael, N. L., Rerks-Ngarm, S., Mathieson, B., Marovich, M., Currier, J. R., and Kim, J. H., “The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.”, J Immunol, vol. 188, no. 10, pp. 5166-76, 2012.